Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq:BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from preclinical testing of its PGN-OB2 program, reporting an average bioavailability of 37% for semaglutide, a GLP-1 receptor agonist. Semaglutide is currently marketed as two subcutaneously administered formulations under the brand names Ozempic® for the treatment of diabetes and Wegovy® for weight management. An oral formulation of a GLP-1 molecule that uses a different delivery technology, brand name Rybelsus®, is also currently marketed for the treatment of diabetes, with studies demonstrating bioavailability of less than 1%.1
Related news for (BIOR)
- biora therapeutics announces $3 million registered direct offering priced at-the-market under nasdaq rules
- biora therapeutics shares progress on smaller biojet™ clinical device with largest payload of any ingestible injectable at the 14th annual podd meeting
- biora therapeutics to reveal 00-size biojet™ device at the 14th annual partnership opportunities in drug delivery meeting
- biora therapeutics to present at the 19th annual peptide therapeutics symposium
- biora therapeutics announces award-winning abstract to be presented at american college of gastroenterology annual scientific meeting 2024